XELOX和OLF方案治療晚期胃癌的臨床研究.pdf

1、內(nèi)蒙古醫(yī)學(xué)院碩士學(xué)位論文XELOX和OLF方案治療晚期胃癌的臨床研究姓名：杜春申請(qǐng)學(xué)位級(jí)別：碩士專業(yè)：內(nèi)科學(xué)指導(dǎo)教師：陳春華20090501壁翌蒙古醫(yī)學(xué)院碩士研究生學(xué)位論文(2009年)AClinicalStudyofXELOXandOLFintheTreatmentOfAdvancedGastricCancerAbstractObjectiveToobservethecomparativeXELOXandOLFinthetreatme

2、ntofadvancedgastricc821cerpatientswithshort—termefficacy，clinicalbenefitresponse，disease—freetimetoprogressionandaveragelengthofstay，medicalexpensesandtoxicityMethods30c雕；鶴diagnosedbyhistopathologyinpatients、^疽thadvanced

3、gastricadenocarcinomawererandomlydividedinto[3^rogroups，XELOXgroup：Xeloda1000mg／m2／d，twooralpost—prandial，dl—d14，Oxaliplatin(L—OHP)130mg／m2，intravenousdrip2hdl，every3weeksforonecycleOLFgroup：Oxaliplatin(L—OHP)130mg／m2，in

4、travenousinfusionof2h，dlcalciumfolinate(C：F)200mWm2，intravenousinfusionof2h，dl一5，5一fluorouracil(5一FU)500m避／m2，intravenousinfusionof6h，dl一5，every3weeksforonecycleAftertwocyclesofchemotherapywereevaluatedTheresultsXELOXand

5、OLFgroupshave15oAtsesofadvancedgastricadenoearcinomapatientsreceivingthetherapy，XE—LOXgroupinwhichsevencasesofnewlydiagnosedpatients，8c硼ofre—treatedpa—tients，OLFgroupofeighteasesofpreviouslyuntreatedpatients，sevellcaseso

6、fre—treatedpatientsCanevaluatetheefficacyandtoxicityinpatientswithXELOXgroup15cases，OLFgroupof14casesXELOXandOLFgroupsrecentlyhavetheeffideneyof365％，re—spectively，and357％(P005)，Clinicalbenefitresponserateswere533％and500％

7、(p005)，XELOXandOLFgroupleukocytetoxicityrateswere467％，50O％，Theincidenceofredbloodcelltoxicitywere200％，214％，Platelettoxicityrateswere133％，143％，Non—hematologictoxicityofXELOXandOLFgrouptheincidenceofhand—footsyndromewere20